Posts

Recent Biotech Reverse Mergers Accelerate BTK‑Based Immune & Inflammatory Drug Programs

on

Lilly oncology chief went from extremely nervous to blown away by new Jaypirca CLL data

on

BeOne's Beqalzi wins FDA accelerated approval as first BCL-2 inhibitor for mantle cell lymphoma

on

Roche's Fenebrutinib Delays MS Relapses in Phase 3 Trials but Faces Liver Toxicity and Safety Scrutiny

on

Sanofi calls FDA rejection of potential MS blockbuster tolebrutinib “unexpected” amid evolving agency views on benefit–risk

on

Zenas BioPharma Inks $2 Billion+ Licensing Deal With InnoCare for Autoimmune Drug Candidates

on

FDA Delays Decision on Sanofi's Oral Multiple Sclerosis Drug to December 2025

on

Eli Lilly Touts 'Striking' Progression-Free Survival Results for Jaypirca in New Front-Line CLL Study

on

Sanofi’s Wayrilz Receives FDA Approval as First BTK Inhibitor for Immune Thrombocytopenia

on

Jaypirca Demonstrates Superior Efficacy Over Imbruvica in BTK Inhibitor Clash for CLL/SLL

on

AstraZeneca's Calquence Combo Approved for First-Line CLL in EU

on